Davies Robert
School of Biomedical and Healthcare Sciences, University of Plymouth School of Biological Sciences, Plymouth, UK.
Clin Kidney J. 2018 Oct;11(5):694-703. doi: 10.1093/ckj/sfy037. Epub 2018 Jun 2.
Chronic kidney disease (CKD) is a growing burden on people and on healthcare for which the diagnostics are niether disease-specific nor indicative of progression. Biomarkers are sought to enable clinicians to offer more appropriate patient-centred treatments, which could come to fruition by using a metabolomics approach. This mini-review highlights the current literature of metabolomics and CKD, and suggests additional factors that need to be considered in this quest for a biomarker, namely the diet and the gut microbiome, for more meaningful advances to be made.
慢性肾脏病(CKD)给人们和医疗保健带来的负担日益加重,其诊断既非疾病特异性的,也不能指示疾病进展。人们一直在寻找生物标志物,以使临床医生能够提供更合适的以患者为中心的治疗方法,而这可以通过代谢组学方法来实现。本综述强调了代谢组学和CKD的当前文献,并提出在寻找生物标志物的过程中需要考虑的其他因素,即饮食和肠道微生物群,以便取得更有意义的进展。